Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Home

sheeba farhat

Articles By : sheeba farhat

Zydus Completes Agenus Deal, Launches US-Based Biologics CDMO Arm Zylidac Bio

sheeba farhat16 Jan 2026 11:16 PM IST

New Delhi: Zydus Lifesciences Limited has announced the successful closure of the Asset Purchase Agreement, Share Purchase Agreement, and the...

Sun Pharma Launches UNLOXCYT for Advanced Skin Cancer in US

sheeba farhat16 Jan 2026 10:13 PM IST

New Delhi: Sun Pharmaceutical Industries Limited has announced that UNLOXCYT (cosibelimab-ipdl) is now available in the United States for prescription...

USFDA Halts Fast-Track Reviews of Disc, Sanofi Drugs Over Safety, Death Concerns

sheeba farhat16 Jan 2026 9:02 PM IST

They also stalled their review of French drugmaker Sanofi's Tzield for late-stage type 1 diabetes by more than a month over adverse event reports,...

UP: Govt Supplied Medicines Including Cough Syrups, Iron Tablets Found Dumped in Canal, Probe Ordered

sheeba farhat16 Jan 2026 6:42 PM IST

Based on preliminary observations, officials suspect that the medicines may have been deliberately disposed of by staff of a health facility.

Zydus Bags USFDA Nod for Eltrombopag Tablets Across Four Strengths

sheeba farhat15 Jan 2026 5:06 PM IST

Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders.

Venus Remedies Secures Marketing Authorisation For Ceftazidime, Avibactam FDC In Indonesia

sheeba farhat15 Jan 2026 2:20 PM IST

This approval represents Venus Remedies' first marketing authorization in the anti-infective segment in Indonesia and also enables the first generic...

USFDA, EMA Issue First Joint Guidelines on Safe Use of AI in Drug Development

sheeba farhat15 Jan 2026 2:02 PM IST

The move comes as regulators push to expand the use of AI in drug discovery and development to shorten timeline and reduce animal testing.

No Link to Suicidal Thoughts: USFDA Seeks Label Change for Popular Weight-Loss Drugs Wegovy, Zepbound

sheeba farhat14 Jan 2026 6:57 PM IST

The warnings, part of their original approval, were based on reports of such events observed with a variety of older medicines used or studied ‌for...

USFDA Approves Bionpharma's Generic HIV Drug Etravirine

sheeba farhat14 Jan 2026 5:40 PM IST

The product was developed using STEERLife's FragMelt continuous processing platform, which enables solvent-free manufacturing while maintaining...

India to Move From Make to Discover and Make in Pharma: Amit Shah at PAGE Launch

India to Move From 'Make' to 'Discover & Make' in Pharma: Amit Shah at PAGE Launch

sheeba farhat14 Jan 2026 4:39 PM IST

PAGE is an industry-led national skilling initiative of the (IPA) companies.

Zydus-Owned Sentynl Gets USFDA Nod for First-Ever Menkes Disease Treatment ZYCUBO

sheeba farhat14 Jan 2026 10:57 AM IST

ZYCUBO is a subcutaneous injectable formulation of copper histidinate designed to restore copper homeostasis and maintain adequate copper levels in...

Novo Nordisk Projects Oral Weight-Loss Pills to Take One-Third of GLP-1 Market by 2030

sheeba farhat13 Jan 2026 5:23 PM IST

Novo launched a daily oral version of Wegovy in the U.S. earlier this month with a starting cash price of USD 149 per month.

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok